Tag Archives: BIRB-796

Characterisation of p38 switch pocket inhibitors

Doramapimod (BIRB-796), from Boehringer Ingelheim, was the first reported  inhibitor of p38 which did not bind to the canonical ATP site.  This opened up the prospect of allosteric inhibition of kinases as a viable approach to identifying novel drug candidates. This … Continue reading

Posted in Kinase Inhibitors | Tagged , , , , , , , , | Leave a comment